AU2002364954A1 - ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS - Google Patents

ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Info

Publication number
AU2002364954A1
AU2002364954A1 AU2002364954A AU2002364954A AU2002364954A1 AU 2002364954 A1 AU2002364954 A1 AU 2002364954A1 AU 2002364954 A AU2002364954 A AU 2002364954A AU 2002364954 A AU2002364954 A AU 2002364954A AU 2002364954 A1 AU2002364954 A1 AU 2002364954A1
Authority
AU
Australia
Prior art keywords
blys
antibodies
immunospecifically bind
immunospecifically
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002364954A
Other versions
AU2002364954A8 (en
Inventor
Steven C. Barash
Gil H. Choi
David Hilbert
Steven M. Ruben
Tristan J. Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU2002364954A8 publication Critical patent/AU2002364954A8/en
Publication of AU2002364954A1 publication Critical patent/AU2002364954A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002364954A 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS Abandoned AU2002364954A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19
PCT/US2002/036496 WO2003055979A2 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Publications (2)

Publication Number Publication Date
AU2002364954A8 AU2002364954A8 (en) 2003-07-15
AU2002364954A1 true AU2002364954A1 (en) 2003-07-15

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364954A Abandoned AU2002364954A1 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Country Status (4)

Country Link
EP (1) EP1456347A4 (en)
AU (1) AU2002364954A1 (en)
CA (1) CA2467521A1 (en)
WO (1) WO2003055979A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
MXPA01007464A (en) 1999-01-25 2003-06-06 Apoxis Sa Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses.
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
PT2281843T (en) 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
PT2272868E (en) 2003-06-05 2015-07-07 Genentech Inc Combination therapy for b cell disorders
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
KR100924044B1 (en) 2004-03-31 2009-10-27 캐논 가부시끼가이샤 Structure for capturing target substance
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1826218B1 (en) * 2004-08-31 2014-01-01 Kowa Company, Ltd. Antihuman baff antibody
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EA030313B1 (en) 2007-03-27 2018-07-31 Займодженетикс, Инк. METHOD OF REDUCING LEVELS OF IgM, IgG AND IgA IN MAMMALS AND COMPOSITION FOR IMPLEMENTATION THEREOF
AR068767A1 (en) 2007-10-12 2009-12-02 Novartis Ag ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN103421113B (en) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 Anti- BLyS antibody
CN104045713B (en) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody
US20210347873A1 (en) * 2016-07-06 2021-11-11 Shanghai Pharmaexplorer Co., Ltd. Blys antibody, preparation method therefor and application thereof
CA3051865C (en) 2017-02-01 2023-01-17 Yale University Treatment of diuretic resistance
CN111787950A (en) 2018-01-05 2020-10-16 科威迪亚治疗公司 Methods for treating IL-6 mediated inflammation without immunosuppression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329610T1 (en) * 2000-02-16 2006-07-15 Genentech Inc ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
ATE361318T1 (en) * 2000-05-12 2007-05-15 Amgen Inc POLYPEPTIDES THAT INHIBIT APRIL-MEDIATED ACTIVATION OF T AND B CELLS
PT2281843T (en) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP2301971A1 (en) * 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI

Also Published As

Publication number Publication date
EP1456347A2 (en) 2004-09-15
AU2002364954A8 (en) 2003-07-15
WO2003055979A2 (en) 2003-07-10
EP1456347A4 (en) 2006-08-02
WO2003055979A3 (en) 2003-12-18
CA2467521A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2002364954A1 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP1572874A3 (en) Antibodies that immunospecifically bind to trail receptors
CY2012003I1 (en) ANTIBODIES THAT BIND IMMUNOSPECIFICALLY TO BLYS
EP1465925A4 (en) Antibodies that immunospecifically bind to trail receptors
HK1075470A1 (en) Antibodies that immunospecifically bind to trail receptors
EP2270052B8 (en) Antibodies to OPGL
IL213564A0 (en) Antibodies to vla-1
EP1494693A4 (en) Cripto-specific antibodies
AU2002359659A1 (en) Cross reference to related application
AU2003234706A1 (en) Antibodies that specifically bind to tl5
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU2003240822A1 (en) Antibodies that specifically bind to neurokinin b
AU2003256299A1 (en) Antibodies that specifically bind to reg iv
AU2002351374A1 (en) Antibodies to treat cancer
AU2003302822A1 (en) Antibodies to treat cancer
AU2606700A (en) Saccharides linked to compounds that bind cell-surface peptides or proteins
AU2002352676A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2003288809A1 (en) Peptides that bind of the vegfr-2
AU2003259835A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2001297702A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2002365894A8 (en) Antibodies to magmas and uses thereof
AU2003228483A1 (en) Antibodies that specifically bind to tr2
GB0226878D0 (en) Antibodies
AU2002304743A1 (en) Cancer treatment by using fap-alpha specific antibodies
AUPR434801A0 (en) Additional examples to pr2596 using seperate pivots

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase